Lundbeck study shows Cipralex better than Seroxat

Lundbeck study shows Cipralex better than Seroxat
Monday, February 27, 2006

Lundbeck study shows Cipralex better than Seroxat

Last Updated: 2006-02-27 13:00:56 -0400 (Reuters Health)

COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck said on Monday new clinical data for its key antidepressant Cipralex showed the drug was superior to GlaxoSmithKline's Seroxat (paroxetine) in the treatment of major depression.

"The data confirms that Cipralex is superior to Seroxat within the treatment of depression", Lundbeck said in a statement.

The study, presented at the International Anxiety Disorders Conference in Stellenbosch, South Africa, was a randomised, double blind, fixed-dose study evaluating Cipralex and Seroxat in the long-term treatment of patients with more severe depressive disorder.

Lundbeck said 229 patients received treatment with Cipralex and 225 patients received treatment with Seroxat, known as Paxil in the United States.

Go Back

Schwartzapfel Partners

With over 150 years of combined experience and highly competent co-counsel throughout the country, we can serve all your legal needs. Schwartzapfel Partners protects the rights of those who aren't able to do so themselves. Learn More

Gender: Male Female

In what state did the incident occur?

Schwartzapfel Truhowsky Marcus
Sachs P.C. disclaimer.